Archives: Search / 2017 / 2016 / 2015 / 2014 / 2013 / 2012 / 2011 / 2010 / 2009 / 2008

200720062004

2016 Archives

Dec 19, 2016

Lannett Company, Inc. (NYSE: LCI) today announced that it received approval from the U.S. Food and Drug Administration (FDA) of its Supplemental New Drug Application (sNDA) for Morphine Sulfate...

More
Dec 7, 2016

Lannett Company, Inc. (NYSE: LCI) today announced that the company will present at the BMO Capital Markets 2016 Prescription for Success Healthcare Conference on December 14, 2016 at 9:20 a.m....

More
Nov 30, 2016

Lannett Company, Inc. (NYSE: LCI) today announced that the U.S. Food and Drug Administration (FDA) granted the company a 90-day extension to submit documentation concerning its Methylphenidate...

More
Nov 28, 2016

Lannett Company, Inc. (NYSE: LCI) today announced that it received approval from the U.S. Food and Drug Administration (FDA) of its Abbreviated New Drug Application (ANDA) for Metaxalone Tablets...

More
Nov 14, 2016

Lannett Company, Inc. (NYSE: LCI) today announced that it received approval from the U.S. Food and Drug Administration (FDA) of its Abbreviated New Drug Application (ANDA) for Memantine...

More
Nov 9, 2016

Lannett Company, Inc. (NYSE: LCI) today announced that the company will present at the Jefferies London Healthcare Conference on November 16, 2016 at 2:40 p.m. (GMT) at the Waldorf Hilton hotel in...

More
Nov 3, 2016
--Net Sales Increased 52% to Approximately $162 Million; Company Revises Guidance for Fiscal 2017--

Lannett Company, Inc. (NYSE: LCI) today reported financial results for its fiscal 2017 first quarter ended September 30, 2016. The company completed the acquisition of Kremers Urban...

More
Oct 27, 2016

Lannett Company, Inc. (NYSE: LCI) today announced successful results from a placebo-controlled Phase III clinical study evaluating C-TopicalĀ® (cocaine hydrochloride solution) 4% and 10% as a...

More
Oct 27, 2016

Lannett Company, Inc. (NYSE: LCI) today announced that it will report financial results for its fiscal 2017 first quarter on Thursday, November 3, 2016, after the market closes. Lannett management...

More
Oct 19, 2016

Lannett Company, Inc. (NYSE: LCI) received a notice from the U.S. Food and Drug Administration (FDA) that it will seek to withdraw approval of the Company's Abbreviated New Drug Application (ANDA)...

More
Sep 22, 2016

Lannett Company, Inc. (NYSE: LCI) today announced the resignation of its chief of scientific affairs, Mahendra Dedhiya, Ph.D., effective October 21, 2016. "Mahendra joined Lannett last year as...

More
Sep 20, 2016

Lannett Company, Inc. (NYSE: LCI) today announced that it received approval from the U.S. Food and Drug Administration (FDA) of its Abbreviated New Drug Application (ANDA) for Buprenorphine and...

More
Sep 19, 2016

Lannett Company, Inc. (NYSE: LCI) today announced that the U.S. Food and Drug Administration (FDA) recently completed a cGMP inspection of the company's manufacturing facility in Philadelphia, as...

More
Aug 23, 2016
--Company Reports Fourth Quarter Net Sales Increased 70% to Approximately $169 Million, GAAP Diluted EPS of $0.10, Adjusted Diluted EPS of $0.73; Provides Guidance for Fiscal 2017--

Lannett Company, Inc. (NYSE: LCI) today reported financial results for its fiscal 2016 fourth quarter and full year ended June 30, 2016. As previously announced, the company completed the...

More
Aug 17, 2016

Lannett Company, Inc. (NYSE: LCI) today announced that it will report financial results for its fiscal 2016 fourth quarter and full year on Tuesday, August 23, 2016, after the market closes....

More
Jul 25, 2016
--Company Appoints Kristie Stephens Vice President Regulatory Affairs and Chief Compliance Officer and John Kozlowski Vice President Financial Operations and Corporate Controller--

Lannett Company, Inc. (NYSE: LCI) today announced two promotions. Kristie Stephens has been appointed vice president of regulatory affairs and chief compliance officer, and John Kozlowski has been...

More
Jul 20, 2016

Lannett Company, Inc. (NYSE: LCI) today announced that its strategic partner, Sparsha Pharma USA, Inc., has received an Acceptable for Filing letter from the U.S. Food and Drug Administration...

More
Jul 11, 2016

Lannett Company, Inc. (NYSE: LCI) today announced that it recently received approval from the U.S. Food and Drug Administration (FDA) of its Abbreviated New Drug Application (ANDA) for Paroxetine...

More
Jun 28, 2016

Lannett Company, Inc. (NYSE: LCI) today announced that it has received approval from the U.S. Food and Drug Administration (FDA) of its Abbreviated New Drug Application (ANDA) for Diazepam Oral...

More
Jun 20, 2016
--Overcomes Volatile Market to Achieve Significant Interest Savings--

Lannett Company, Inc. (NYSE: LCI) today announced that it has completed the repurchase of the remaining $200 million of the 12% Senior Notes due in 2023, after successfully amending its existing...

More
Jun 14, 2016
--Company Previously Completed the Repurchase of $50 Million of 12% Senior Notes--

Lannett Company, Inc. (NYSE: LCI) today announced that it has reached an agreement with an existing lender to raise an incremental $150 million Term Loan B, and is also seeking to amend certain...

More
Jun 13, 2016

Lannett Company, Inc. (NYSE: LCI) today announced that it has received approval from the U.S. Food and Drug Administration (FDA) of its Abbreviated New Drug Application (ANDA) for Neomycin Sulfate...

More
May 27, 2016

Lannett Company, Inc. (NYSE: LCI) today announced that it has completed the repurchase of $50 million of the $250 million aggregate principal amount of the 12% Senior Notes due in 2023 in open...

More
May 26, 2016

Lannett Company, Inc. (NYSE: LCI) today announced that it expects to repurchase $50 million of the $250 million aggregate principal amount of the 12% Senior Notes due in 2023 in open market...

More
May 5, 2016

Lannett Company, Inc. (NYSE: LCI) today announced that the company will present at the Bank of America Merrill Lynch 2016 Health Care Conference on May 11, 2016 at 3:40 p.m. PT at the Encore at...

More
 

print email rss
Lannett Investor Relations
Lannett Company Products